News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ARTES Biotechnology Announces a Strategic Collaboration Deal for Vaccine Development


4/24/2012 9:54:26 AM

Langenfeld, Germany, April 24, 2012 / B3C newswire / - ARTES Biotechnology, specialized in recombinant protein production and process development in microbial expression systems, started a development collaboration for two vaccines together with global biopharmaceutical company Crucell. Crucell is focused on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide.

Aim of the long-term research cooperation is a new-product development on the basis of ARTES’ virus like particle (VLP) and the well-established Hansenula polymorpha expression system fitting to Crucell’s vaccine portfolio. The Hansenula system is the preferred technology for affordable mass vaccination and is recommended by the WHO for hepatitis B vaccination campaigns. In combination, the unique yeast based VLP approach builds a new and very economical approach to low-cost mass production of safe and effective vaccines.

Under the terms of the long-term research collaboration ARTES is responsible for delivery of the production cell lines and processes to Crucell.

ARTES Biotechnology GmbH

ARTES is a Germany-based biotechnology company specialized in recombinant protein production and process development from microbial expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld. The company focuses on contract R&D for red and white biotechnology products.

Contact

ARTES Biotechnology GmbH

Dr. Melanie Piontek

Business Development Director

+49 (0)2173 275870

piontek@artes-biotechnology.com


Read at BioSpace.com

comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES